ArticleAntimicrobial agents and chemotherapy2013
Molecular characterization and in vitro antifungal susceptibility profile of Schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Emerging Filamentous Basidiomycetes as Opportunistic Human Pathogens: Diagnostic and Antifungal Challenges in a Tertiary-Care Center in Thailand.Antibiotics (Basel, Switzerland) · 2026Article
- Antifungal susceptibility and molecular characterization of clinical and environmental isolates ofJournal of clinical microbiology · 2026Article
- Recurrent Pulmonary Infection Caused byRespirology case reports · 2025Article
- Traumatic implantation keratitis caused byMedical mycology case reports · 2024Article
- Clinical characteristics of allergic bronchopulmonary mycosis caused by Schizophyllum commune.Clinical and translational allergy · 2024Article
- Subcutaneous mycosis caused by filamentous basidiomyceteMedical mycology case reports · 2023Article
- A Schizophyllum commune fungus ball in a lung cancer cavity: a case report.BMC infectious diseases · 2021Article
- A case of primary pulmonary Schizophyllum commune empyema treated with video-assisted thoracoscopic decortication.General thoracic and cardiovascular surgery · 2021Article
- Hormographiella aspergillata: an emerging basidiomycete in the clinical setting? A case report and literature review.BMC infectious diseases · 2020Review
- Article
- Article
- Allergic Bronchopulmonary Mycosis Due to Schizophyllum commune Treated Effectively with Voriconazole.Internal medicine (Tokyo, Japan) · 2018Article
- Coelomycetous Fungi in the Clinical Setting: Morphological Convergence and Cryptic Diversity.Journal of clinical microbiology · 2017Article
- Schizophyllum radiatum, an Emerging Fungus from Human Respiratory Tract.Journal of clinical microbiology · 2016Article
- Schizophyllum commune-induced Pulmonary Mycosis.Chinese medical journal · 2016Article
- First report of otitis externa caused by Schizophyllum commune and review of the literature.Wiener klinische Wochenschrift · 2016Review
- Schizophyllum commune-induced allergic fungal rhinosinusitis and sinobronchial mycosis.Medical mycology case reports · 2015Article
- Atopic cough and fungal allergy.Journal of thoracic disease · 2014Review
- Fatal empyema thoracis caused by Schizophyllum commune with cross-reactive cryptococcal antigenemia.Journal of clinical microbiology · 2014Article
- Implications of high antifungal susceptibility on Schizophyllum commune-associated allergy in clinical practice.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophyllum commune (n = 30) showed lowest geometric mean MICs of isavuconazole (0.19 μg/ml), itraconazole (0.2 μg/ml), voriconazole (0.24 μg/ml), and amphotericin B (0.29 μg/ml) and high geometric mean MICs of fluconazole (19.39 μg/ml) and flucytosine (17.28 μg/ml). Five cases (of 8) of allergic bronchopulmonary mycosis that were treated with itraconazole had no recrudescence after 6 to 24 months of follow-up. One case each of invasive pulmonary mycosis and fungal ball were treated successfully with voriconazole and itraconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.